{"created":"2023-06-19T10:43:56.644068+00:00","id":4297,"links":{},"metadata":{"_buckets":{"deposit":"0026294d-7fc4-4530-9151-ec6a454eeac3"},"_deposit":{"created_by":11,"id":"4297","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"4297"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00004297","sets":["77:78:79"]},"author_link":["8708","675","674"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"7","bibliographicPageEnd":"823","bibliographicPageStart":"814","bibliographicVolumeNumber":"45","bibliographic_titles":[{},{"bibliographic_title":"Biological & pharmaceutical bulletin","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"野田, 哲史"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"森田, 真也"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"寺田, 智祐"}],"nameIdentifiers":[{},{}]}]},"item_4_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"pdf","subitem_description_type":"Other"}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Oral multi-kinase inhibitors have transformed the treatment landscape for various cancer types and provided significant improvements in clinical outcomes. These agents are mainly approved at fixed doses, but the large inter-individual variability in pharmacokinetics and pharmacodynamics (efficacy and safety) has been an unsolved clinical issue. For example, certain patients treated with oral multi-kinase inhibitors at standard doses have severe adverse effects and require dose reduction and discontinuation, yet other patients have a suboptimal response to these drugs. Consequently, optimizing the dosing of oral multi-kinase inhibitors is important to prevent over-dosing or under-dosing. To date, multiple studies on the exposure-efficacy/toxicity relationship of molecular targeted therapy have been attempted for the implementation of therapeutic drug monitoring (TDM) strategies. In this milieu, we recently conducted research on several multi-kinase inhibitors, such as sunitinib, pazopanib, sorafenib, and lenvatinib, with the aim to optimize their treatment efficacy using a pharmacokinetic/pharmacodynamic approach. Among them, sunitinib use is an example of successful TDM implementation. Sunitinib demonstrated a significant correlation between drug exposure and treatment efficacy or toxicities. As a result, TDM services for sunitinib has been covered by the National Health Insurance program in Japan since April 2018. Additionally, other multi-kinase targeted anticancer drugs have promising data regarding the exposure-efficacy/toxicity relationship, suggesting the possibility of personalization of drug dosage. In this review, we provide a comprehensive summary of the clinical evidence for dose individualization of multi-kinase inhibitors and discuss the utility of TDM of multi-kinase inhibitors, especially sunitinib, pazopanib, sorafenib, and lenvatinib.","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"The Pharmaceutical Society of Japan"}]},"item_4_publisher_34":{"attribute_name":"別言語の出版者","attribute_value_mlt":[{"subitem_publisher":"日本薬学会"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"35786588","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1248/bpb.b21-01098"}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1248/bpb.b21-01098","subitem_relation_type_select":"DOI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2022 The Pharmaceutical Society of Japan "},{"subitem_rights":"著作権は日本薬学会に帰属"}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1347-5215","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"NODA, Satoshi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"MORITA, Shin-ya"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"TERADA, Tomohiro"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-07-28"}],"displaytype":"detail","filename":"hsf.4479.pdf","filesize":[{"value":"596.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"hsf.4479","url":"https://shiga-med.repo.nii.ac.jp/record/4297/files/hsf.4479.pdf"},"version_id":"04c48270-d48f-4be4-8be7-2e5767623570"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"individualized pharmacotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"oral multi-kinase inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"dose prediction","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"therapeutic drug monitoring","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring."}]},"item_type_id":"4","owner":"11","path":["79"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-07-28"},"publish_date":"2022-07-28","publish_status":"0","recid":"4297","relation_version_is_last":true,"title":["Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T11:12:12.577025+00:00"}